Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

被引：0

作者：

Metz, D. C. ^{[1
]}

Liu, E. ^{[2
]}

Joish, V. N. ^{[3
]}

Huynh, L. ^{[4
]}

Cheng, M. ^{[4
]}

Kunzweiler, C. ^{[4
]}

Duh, M. S. ^{[4
]}

Giacalone, S. ^{[3
]}

Lapuerta, P. ^{[3
]}

Morse, M. A. ^{[5
]}

机构：

[1] Neuroendocrine Tumor Ctr Penn Med, Philadelphia, PA USA

[2] Rocky Mt Canc Ctr, Neuroendocrine Inst, Denver, CO USA

[3] Lexicon Pharmaceut Inc, The Woodlands, TX USA

[4] Anal Grp, Boston, MA USA

[5] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA

来源：

NEUROENDOCRINOLOGY | 2020年 / 110卷

关键词：

neuroendocrine tumor; carcinoid syndrome; telotristat ethyl; serotonin; tumor growth; progression-free survival;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H21

引用

页码：198 / 198

页数：1

共 50 条

[31] Benzodiazepines in clinical practice: Consideration of their long-term use and alternative agents
Stevens, JC
Pollack, MH
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 : 21 - 27
[32] Progression-free survival as an end-point in clinical trials of biotherapeutic agents
Bergmann, Lothar
Hirschfeld, Steven
Morris, Charles
Palmeri, Sergio
Stone, Andrew
EJC SUPPLEMENTS, 2007, 5 (09): : 23 - 28
[33] Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma
Hotte, S. J.
Bjarnason, G. A.
Heng, D. Y. C.
Jewett, M. A. S.
Kapoor, A.
Kollmannsberger, C.
Maroun, J.
Mayhew, L. A.
North, S.
Reaume, M. N.
Ruether, J. D.
Soulieres, D.
Venner, P. M.
Winquist, E. W.
Wood, L.
Yong, J. H. E.
Saad, F.
CURRENT ONCOLOGY, 2011, 18 : S11 - S19
[34] Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
Gill, S.
Berry, S.
Biagi, J.
Butts, C.
Buyse, M.
Chen, E.
Jonker, D.
Marginean, C.
Samson, B.
Stewart, J.
Thirlwell, M.
Wong, R.
Maroun, J. A.
CURRENT ONCOLOGY, 2011, 18 : S5 - S10
[35] Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit
Ozols, RF
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2451 - 2453
[36] Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials
Ascierto, Paolo A.
Long, Georgina V.
LANCET ONCOLOGY, 2016, 17 (08): : 1037 - 1039
[37] CLINICAL COURSE AND PROGRESSION-FREE SURVIVAL OF ADULT AND PEDIATRIC EPENDYMOMA: A WORKING MODEL
Vera-Bolanos, Elizabeth
Gilbert, Mark R.
Aldape, Kenneth
Necesito-Reyes, Mary Jo
Fouladi, Maryam
Gajjar, Amar
Goldman, Stewart
Metellus, Philippe
Mikkelsen, Tom
Omuro, Antonio
Packer, Roger
Partap, Sonia
Pollack, Ian F.
Prados, Michael
Robins, H. Ian
Soffietti, Riccardo
Wu, Jing
Armstrong, Terri S.
NEURO-ONCOLOGY, 2012, 14 : 77 - 77
[38] Joint modeling of progression-free survival and death in advanced cancer clinical trials
Dejardin, David
Lesaffre, Emmanuel
Verbeke, Geert
STATISTICS IN MEDICINE, 2010, 29 (16) : 1724 - 1734
[39] Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas
Davison, Mark A.
Lilly, Daniel T.
Patel, Arpan A.
Kashkoush, Ahmed
Chen, Xiaoying
Wei, Wei
Benzel, Edward C.
Prayson, Richard A.
Chao, Samuel
Angelov, Lilyana
JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (03) : 437 - 446
[40] Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Vera-Bolanos, Elizabeth
Aldape, Kenneth
Yuan, Ying
Wu, Jimin
Wani, Khalida
Necesito-Reyes, Mary Jo
Colman, Howard
Dhall, Girish
Lieberman, Frank S.
Metellus, Philippe
Mikkelsen, Tom
Omuro, Antonio
Partap, Sonia
Prados, Michael
Robins, H. Ian
Soffietti, Riccardo
Wu, Jing
Gilbert, Mark R.
Armstrong, Terri S.
NEURO-ONCOLOGY, 2015, 17 (03) : 440 - 447

← 1 2 3 4 5 →